Eos Management L.P. Has $5.98 Million Holdings in Danaher Co. (NYSE:DHR)

Eos Management L.P. increased its stake in shares of Danaher Co. (NYSE:DHR) by 18.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,030 shares of the conglomerate’s stock after acquiring an additional 4,052 shares during the period. Danaher comprises about 2.5% of Eos Management L.P.’s portfolio, making the stock its 11th largest position. Eos Management L.P.’s holdings in Danaher were worth $5,975,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Kovack Advisors Inc. lifted its holdings in shares of Danaher by 3.4% in the third quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock valued at $346,000 after purchasing an additional 41 shares in the last quarter. Gilbert & Cook Inc. raised its position in Danaher by 2.5% in the 4th quarter. Gilbert & Cook Inc. now owns 1,749 shares of the conglomerate’s stock valued at $401,000 after buying an additional 42 shares during the last quarter. Grimes & Company Inc. lifted its stake in Danaher by 0.6% in the 4th quarter. Grimes & Company Inc. now owns 7,390 shares of the conglomerate’s stock valued at $1,696,000 after acquiring an additional 43 shares in the last quarter. Harbour Investments Inc. boosted its position in Danaher by 3.0% during the 3rd quarter. Harbour Investments Inc. now owns 1,531 shares of the conglomerate’s stock worth $426,000 after acquiring an additional 45 shares during the last quarter. Finally, Dakota Community Bank & Trust NA raised its holdings in shares of Danaher by 16.4% in the fourth quarter. Dakota Community Bank & Trust NA now owns 320 shares of the conglomerate’s stock valued at $73,000 after purchasing an additional 45 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Stock Down 3.3 %

Danaher stock opened at $205.02 on Tuesday. Danaher Co. has a twelve month low of $196.80 and a twelve month high of $281.70. The stock has a market cap of $146.53 billion, a P/E ratio of 38.83, a P/E/G ratio of 2.66 and a beta of 0.82. The company’s 50-day moving average price is $222.02 and its two-hundred day moving average price is $242.18. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last released its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the previous year, the company posted $2.09 earnings per share. As a group, analysts expect that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.62%. The ex-dividend date is Friday, March 28th. This is a boost from Danaher’s previous quarterly dividend of $0.27. Danaher’s payout ratio is presently 24.24%.

Insider Activity at Danaher

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. The trade was a 21.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 11.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on DHR shares. Guggenheim began coverage on shares of Danaher in a report on Thursday, December 19th. They set a “buy” rating and a $275.00 target price for the company. Jefferies Financial Group decreased their price objective on Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a report on Wednesday, January 29th. Scotiabank began coverage on Danaher in a report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 target price on the stock. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Finally, Robert W. Baird dropped their price objective on Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 28th. Seven investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.